Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 2
1975 3
1978 2
1980 2
1981 1
1982 2
1983 5
1984 4
1985 4
1986 1
1987 3
1988 6
1989 4
1990 7
1991 2
1992 6
1993 5
1994 6
1995 5
1996 4
1997 8
1998 8
1999 4
2000 7
2001 5
2002 4
2003 15
2004 7
2005 8
2006 16
2007 15
2008 8
2009 12
2010 14
2011 15
2012 12
2013 17
2014 22
2015 30
2016 27
2017 27
2018 21
2019 21
2020 19
2021 21
2022 14
2023 12
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

407 results

Results by year

Filters applied: . Clear all
Page 1
Polycystic kidney disease.
Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE. Bergmann C, et al. Among authors: torres ve. Nat Rev Dis Primers. 2018 Dec 6;4(1):50. doi: 10.1038/s41572-018-0047-y. Nat Rev Dis Primers. 2018. PMID: 30523303 Free PMC article. Review.
New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race.
Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, Grams ME, Greene T, Grubb A, Gudnason V, Gutiérrez OM, Kalil R, Karger AB, Mauer M, Navis G, Nelson RG, Poggio ED, Rodby R, Rossing P, Rule AD, Selvin E, Seegmiller JC, Shlipak MG, Torres VE, Yang W, Ballew SH, Couture SJ, Powe NR, Levey AS; Chronic Kidney Disease Epidemiology Collaboration. Inker LA, et al. Among authors: torres ve. N Engl J Med. 2021 Nov 4;385(19):1737-1749. doi: 10.1056/NEJMoa2102953. Epub 2021 Sep 23. N Engl J Med. 2021. PMID: 34554658 Free PMC article.
Autosomal dominant polycystic kidney disease.
Torres VE, Harris PC, Pirson Y. Torres VE, et al. Lancet. 2007 Apr 14;369(9569):1287-1301. doi: 10.1016/S0140-6736(07)60601-1. Lancet. 2007. PMID: 17434405 Review.
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.
Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE. Chebib FT, et al. Among authors: torres ve. J Am Soc Nephrol. 2018 Oct;29(10):2458-2470. doi: 10.1681/ASN.2018060590. Epub 2018 Sep 18. J Am Soc Nephrol. 2018. PMID: 30228150 Free PMC article. Review.
Polycystic kidney disease.
Harris PC, Torres VE. Harris PC, et al. Among authors: torres ve. Annu Rev Med. 2009;60:321-37. doi: 10.1146/annurev.med.60.101707.125712. Annu Rev Med. 2009. PMID: 18947299 Free PMC article. Review.
Polycystic Kidney Disease, Autosomal Dominant.
Harris PC, Torres VE. Harris PC, et al. Among authors: torres ve. 2002 Jan 10 [updated 2022 Sep 29]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2002 Jan 10 [updated 2022 Sep 29]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301424 Free Books & Documents. Review.
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121377 Free PMC article. Clinical Trial.
Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype.
Senum SR, Li YSM, Benson KA, Joli G, Olinger E, Lavu S, Madsen CD, Gregory AV, Neatu R, Kline TL, Audrézet MP, Outeda P, Nau CB, Meijer E, Ali H, Steinman TI, Mrug M, Phelan PJ, Watnick TJ, Peters DJM, Ong ACM, Conlon PJ, Perrone RD, Cornec-Le Gall E, Hogan MC, Torres VE, Sayer JA; Genomics England Research Consortium, the HALT PKD, CRISP, DIPAK, ADPKD Modifier, and TAME PKD studies; Harris PC. Senum SR, et al. Among authors: torres ve. Am J Hum Genet. 2022 Jan 6;109(1):136-156. doi: 10.1016/j.ajhg.2021.11.016. Epub 2021 Dec 9. Am J Hum Genet. 2022. PMID: 34890546 Free PMC article.
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators. Torres VE, et al. N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4. N Engl J Med. 2017. PMID: 29105594 Free article. Clinical Trial.
407 results